Role of Sleep Disturbance in the Trajectory of Alzheimer’s Disease

Abstract

Sleep disturbances such as insomnia, hypersomnia, and circadian rhythm disturbance are common in normal elderly and Alzheimer’s disease (AD) patients. To date, special attention has been paid to sleep disturbance in the clinical course of AD insofar as the interaction of sleep disturbance with the pathogenesis of AD may impact the clinical course and cognitive function of AD patients. This review covers the bidirectional relationship between sleep disturbance and AD pathogenesis; the associations between sleep disturbance and AD-specific neurotransmitters, brain structure, and aspects of sleep disturbance in each phase of AD; and the effects of sleep disturbance on the cognitive functions of patients in each phase of AD. We consider several factors required to exactly interpret the results and suggest a direction for future studies on the role of sleep disturbance in AD.

Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotype

“…First, sleep disturbance is treatable, and common behavioral treatments have established efficacy in cancer patient populations . Although our findings are correlative, not causal, additional data from noncancer populations support the possibility of causal relationships . A failure to assess and treat patients for sleep disturbance could potentially have a long‐term impact on their risk for later cognitive difficulties.…”

“…Our findings extend the existing evidence that has linked sleep disturbance with cognitive decline and dementia risk in noncancer populations. [7][8][9][10] This prior research points to a 2-hit effect of an APOE ε4 carrier status and sleep disruption on neurofibrillary tangles and the incidence of AD in noncancer populations. 18 APOE ε4 has also been reported in association with cognitive declines in cancer patient populations.…”

“…Sleep disturbance has been identified as a risk factor for the development of cognitive decline and Alzheimer disease (AD) in noncancer populations . Likewise, a number of genetic vulnerabilities for cognitive decline in later life, including variants in the APOE , COMT , and BDNF genes, have been identified.…”

“…[4][5][6] Sleep disturbance has been identified as a risk factor for the development of cognitive decline and Alzheimer disease (AD) in noncancer populations. [7][8][9][10] Likewise, a number of genetic vulnerabilities for cognitive decline in later life, including variants in the APOE, 11,12 COMT, 13,14 and BDNF genes, [15][16][17] have been identified. Prior research has proposed that these genetic variants increase the risk for cognitive decline in general populations and in cancer survivors after treatment and that specific vulnerability factors may interact in accelerating this risk (ie, a gene-environment interaction).…”

[P3–369]: Diagnostic Validity of an Automated Probabilistic Tractography in Amnestic Mild Cognitive Impairment

“…The tracts showed decreased WM integrity in our results were interestingly overlapped with previously reported regions of connectivity problem resting-state fMRI studies. Disruption of functional connectivity of default mode network was observed in previous studies [46][47][48][49] at posterior parietal cortex, the precuneus, posterior and anterior cingulated cortex, medial prefrontal cortex, hippocampus and thalamus. Further study using fMRI analysis and automated tractography is needed for better revealing of effective neuroimaging tool for aMCI patient.…”